Navigation Links
CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant

- Tyrima Demonstrates Good Safety Profile and Excellent Pharmacokinetic Properties -

RESEARCH TRIANGLE PARK, N.C., March 13, 2007 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, today announced top-line results from a Phase I clinical trial of Tyrima(TM), its lead candidate for the treatment of depression and anxiety. In this study, Tyrima was safe and well tolerated. Tyrima is a member of a novel class of drugs known as reversible inhibitors of monoamine oxidase A, or RIMAs.

The single-dose, placebo-controlled trial evaluated Tyrima in 41 subjects with doses escalating from 5 mg to 120 mg over the course of the study. Tyrima was well tolerated with no clinically significant adverse events even at the highest dose of 120 mg. Tyrima achieved high plasma concentrations that increased linearly with dose, and the favorable pharmacokinetic half-life should permit once or twice daily dosing. None of the safety and tolerability issues commonly associated with conventional monoamine oxidase A inhibitors (MAOIs) were seen in this study.

"The triple mechanism of MAOI antidepressants has the potential to provide enhanced efficacy to the 30% of patients who do not respond to current therapies, but use of these drugs has been limited by their propensity to cause serious side effects," said Dr. Atul Pande, chief medical officer of CeNeRx. "It is therefore encouraging that Tyrima, a selective and reversible MAO inhibitor specifically designed to avoid these side effects, demonstrated a promising safety profile in its first clinical trial, even at the highest dose. These results provide a strong foundation for proceeding to multiple dose safety studies."

Tyrima's unique mechanism elevates the levels of three key neurotransmitters (serotonin, norepinephrine and dopamine) that affect mood and anx iety, in contrast to the leading antidepressants available today that affect only the single neurotransmitter serotonin. This triple action mechanism has the potential for enhanced efficacy while the selective and reversible nature of RIMAs is intended to avoid toxic side effects.

"The excellent safety profile demonstrated in this study is the first confirmation in humans that Tyrima has the potential to deliver on the promise of the RIMA approach, and these positive results represent an important milestone for our company," said Barry Brand, chief executive officer of CeNeRx. "In contrast to other MAO inhibitors, our third generation RIMA series is designed to bind selectively and reversibly, with the goal of significantly reducing the cardiovascular risks and other side effects typically associated with the MAOI class. These safety results, along with the high plasma levels and favorable pharmacokinetics demonstrated in the study, support advancing Tyrima into a multiple dose safety study in late spring."

Tyrima could be the first RIMA antidepressant available in the U.S. market, and it has patent protection through 2026. CeNeRx has worldwide rights to develop and commercialize Tyrima.

The Tyrima Phase l safety trials began in January following a successful review of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration.

About CeNeRx BioPharma

CeNeRx (SEN-er-ex) is a privately held clinical stage company developing and commercializing innovative and improved treatments for diseases of the central nervous system. The company focuses on identifying and developing promising therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. CeNeRx's most advanced compounds, reversible inhibitors of monoamine oxidase, or RIMAs, are in Phase I and late pre-clinical d evelopment for the treatment of major depressive disorder. More information about CeNeRx BioPharma can be found at http://www.cenerx.com.

    Contact:

    GendeLLindheim BioCom Partners

    Barbara Lindheim

    212 918 4650

CONTACT: Barbara Lindheim of GendeLLindheim BioCom Partners,+1-212-918-4650, for CeNeRx BioPharma, Inc.

Web site: http://www.cenerx.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
6. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
7. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
8. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):